With significant hedge fund interest and strong upside, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is one of the most promising robotics stocks.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) is building a clinical case for Aquablation that could redefine its addressable market, with two major prostate cancer study milestones drawing fresh analyst attention to the stock.
On May 28, 2026, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) announced two milestones in its WATER IV prostate cancer clinical program.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) completed enrollment in the WATER IV RP study, a randomized trial comparing Aquablation therapy to radical prostatectomy in 280 patients, the only FDA randomized study of its kind. Primary endpoint results are expected to be presented at the American Urological Association Annual Meeting in spring 2027.
Alongside that, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) received FDA Investigational Device Exemption (IDE) approval for a second protocol, WATER IV AS, which will enroll up to 333 patients globally to evaluate Aquablation therapy versus active surveillance in men with Grade Group 1 and 2 prostate cancer. Patients in both studies will be followed for ten years, with assessments covering disease control and quality-of-life outcomes, including urinary, sexual, and overall function.
That clinical progress drew a bullish response from Wall Street.
On June 24, 2026, Evercore ISI analyst Vijay Kumar initiated coverage of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) with an “Outperform” rating and a $30 price target. Kumar cited Aquablation as having the best clinical evidence in the space and argued that a positive WATER IV trial outcome over the next 12 months could expand the total addressable market into prostate cancer while supporting multiple expansion for the stock.
Procept BioRobotics Corporation (NASDAQ:PRCT) is a commercial-stage surgical robotics company that develops transformative solutions in urology in the U.S. and internationally.
While we acknowledge the risk and potential of PRCT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRCT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
